--- a
+++ b/clusters/9knumclustersv2/clust_1539.txt
@@ -0,0 +1,65 @@
+Treatment with any of the following for prostate cancer within  weeks prior to day  of treatment:
+Prior systemic chemotherapy for prostate cancer.
+Prior cytotoxic chemotherapy for metastatic prostate cancer; prior treatment with genomically-targeted agents, or Provenge is allowed
+History of prior treatment for prostate cancer.
+Subject has received prior radiation therapy or chemotherapy for prostate cancer
+Prior systemic chemotherapy for prostate cancer.
+Prior systemic chemotherapy for prostate cancer
+Previous chemotherapy for prostate cancer
+Prior cytotoxic chemotherapy or biologic therapy for prostate cancer
+Prior radiation to the prostate
+Previous or concurrent cytotoxic chemotherapy for prostate cancer
+Patients who have had any prior chemotherapy or radiotherapy for prostate cancer.
+No treatment with any of the following for prostate cancer within  weeks prior to enrollment:
+No prior chemotherapy for prostate cancer
+Prior immunotherapy or chemotherapy for prostate cancer
+Prior immunotherapy/vaccine therapy for prostate cancer
+Patients who have had prior chemotherapy for prostate cancer
+Prior history of treated prostate cancer
+Previous or concurrent cytotoxic chemotherapy for prostate cancer
+Patients who have had prior chemotherapy, experimental agents for prostate cancer, or patients receiving more than  weeks of prior hormone therapy will be excluded
+Prior or concurrent cytotoxic chemotherapy for prostate cancer; prior chemotherapy for a different cancer is permitted
+Prior systemic chemotherapy for prostate cancer
+Prior or current therapy for prostate cancer
+No prior treatment for prostate cancer
+Prior chemotherapy for prostate cancer
+Prior systemic biologic therapy, including immunotherapy, for prostate cancer;
+Prior definitive treatment of prostate cancer
+Prior chemotherapy or immunotherapy for prostate cancer.
+Prior use of immunotherapy or chemotherapy for prostate cancer
+Prior radiation therapy for prostate cancer
+Prior investigational therapy for prostate cancer
+Prior or concurrent cytotoxic chemotherapy for prostate cancer; prior chemotherapy for a different cancer is permitted
+No prior systemic therapy for metastatic prostate cancer
+Prior chemotherapy, radiation therapy, or immunotherapy for prostate cancer
+Treatment with more than one chemotherapy agent for prostate cancer
+Treatment with cytotoxic chemotherapy for prostate cancer within the previous  weeks prior to randomization, or planned treatment with cytotoxic chemotherapy agents for prostate cancer during the treatment period or follow-up
+COHORT A: Current or prior investigational therapies for prostate cancer, or chemotherapy administered with the intention to treat prostate cancer
+COHORT B: Current or prior investigational therapies for prostate cancer, or chemotherapy administered with the intention to treat prostate cancer
+More than  prior courses of chemotherapy for metastatic prostate cancer
+Patients with prior chemotherapy for nonmetastatic prostate cancer within a year are excluded
+No prior radiation or chemotherapy for prostate cancer treatment
+Prior cytotoxic chemotherapy or biologic therapy for prostate cancer
+Patients must not have been treated with a prior vaccine therapy for prostate cancer
+E . Prior chemotherapy for prostate cancer,
+Previous or concurrent cytotoxic chemotherapy for prostate cancer
+Prior cytotoxic chemotherapy for metastatic prostate cancer
+Prior chemotherapy for prostate cancer
+Have had prior or current prostate cancer therapies:
+Chemotherapy for prostate cancer
+Prior chemotherapy for prostate cancer
+Prior chemotherapy, radiation therapy for the treatment of prostate cancer, or immunotherapy for prostate cancer
+Any prior or concurrent treatment for prostate cancer
+Prior surgery or radiation therapy for prostate cancer
+Prior history of prostate cancer
+SUB-STUDY I: Chemotherapy for prostate cancer
+SUB-STUDY II: Chemotherapy for prostate cancer
+Patient must not have had any prior treatment for prostate cancer
+Patients who have received any prior therapy for prostate cancer with surgery, radiation, and/or chemotherapy
+Chemotherapy for prostate cancer
+Patients who have had chemotherapy or radiotherapy within  months of the study for other diagnoses not related to prostate cancer
+No prior treatment for prostate cancer
+Prior treatment for prostate cancer
+Patients who have received systemic chemotherapy for prostate cancer will not be eligible
+Any prior treatment for prostate cancer
+Concurrent immunotherapy for prostate cancer